Roche announced today that results from the first five Phase III clinical trials show that taspoglutide has met the prim…
Injectable Medication
Novo Nordisk receives US approval for Victoza(R) (liraglutide) for treatment of type 2 diabetes
Novo Nordisk announced that it has received US FDA approval for Victoza® (liraglutide) for the treatment of type 2 diabe…
Novo Nordisk Expects FDA Feedback on Liraglutide Within Days
Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding li…
Exenatide Once Weekly Provided Superior Glucose Control Compared to Byetta in Tests
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes Inc. today announced positive results from a head-to-he…
Phase III Trials Show Roche’s Type 2 Drug Better Than Januvia
The Swiss -based pharmaceuticals and diagnostics company Roche Holding AG announced headline results from the second and…
Novo’s Victoza Awaits Final FDA Approval
Novo Nordisk's CEO, Lars Sorensen, told Reuters at the Reuters Health Summit in New York that the new diabetes drug Vict…
Byetta Safety Label Revised
Today the FDA indicated that the safety label of Byetta would be modified to include potential kidney problems including…
Takeda and Amylin to Co-develop Obesity Treatments
Amylin Pharmaceuticals, Inc. and Takeda Pharmaceuticals Company Limited announced an agreement to co-develop and commerc…
Isis Pharmaceuticals: Positive Phase 2 Data for ISIS 113715
Isis pharmaceuticals announced positive mid-stage trial results for the drug called ISIS 113715. The drug, tested on Ty…
